[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SE7500629L - - Google Patents

Info

Publication number
SE7500629L
SE7500629L SE7500629A SE7500629A SE7500629L SE 7500629 L SE7500629 L SE 7500629L SE 7500629 A SE7500629 A SE 7500629A SE 7500629 A SE7500629 A SE 7500629A SE 7500629 L SE7500629 L SE 7500629L
Authority
SE
Sweden
Prior art keywords
urokinase
solution
neutral
agaropectin
aqueous
Prior art date
Application number
SE7500629A
Other versions
SE434956B (en
Inventor
Y Uemura
K Uriyu
S Funakoshi
Original Assignee
Green Cross Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP1002274A external-priority patent/JPS517751B2/ja
Priority claimed from JP1201674A external-priority patent/JPS517752B2/ja
Application filed by Green Cross Corp filed Critical Green Cross Corp
Publication of SE7500629L publication Critical patent/SE7500629L/xx
Publication of SE434956B publication Critical patent/SE434956B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Urokinase of a high degree of purity is obtained in good yield by adsorption of the urokinase from a contaminated aqueous urokinase solution, e.g. human urine, on an agaropectin-containing water-insoluble polysaccharide, e.g. agar or an agarose, and agaropectin-containing preparation. The polysaccharide is then removed at a weakly acidic to neutral pH, which is set, e.g., using a buffered salt solution, with the urokinase adsorbed thereon by ion formation. After washing out the impurities which may be present, the urokinase is eluted in an ion exchange reaction using an aqueous alkaline solution or a concentrated aqueous, neutral solution of a salt or a neutral amino acid. Purified urokinase is used clinically to a large extent for the therapy of peripheral arterial and venous thromboses and myocardial infarcts, which can be attributed to the formation of fibrin clots in blood vessels.
SE7500629A 1974-01-22 1975-01-21 PLEASE CLEAN AND CONCENTRATE UROKINAS SE434956B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP1002274A JPS517751B2 (en) 1974-01-22 1974-01-22
JP1201674A JPS517752B2 (en) 1974-01-28 1974-01-28

Publications (2)

Publication Number Publication Date
SE7500629L true SE7500629L (en) 1975-07-23
SE434956B SE434956B (en) 1984-08-27

Family

ID=26345171

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7500629A SE434956B (en) 1974-01-22 1975-01-21 PLEASE CLEAN AND CONCENTRATE UROKINAS

Country Status (10)

Country Link
AT (1) AT341079B (en)
AU (1) AU474513B2 (en)
CA (1) CA1028262A (en)
CH (1) CH611314A5 (en)
DE (1) DE2502095C3 (en)
ES (1) ES433961A1 (en)
FR (1) FR2258396B1 (en)
GB (1) GB1476092A (en)
IN (1) IN139029B (en)
SE (1) SE434956B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2444465A1 (en) * 1978-12-22 1980-07-18 Green Cross Corp Antithrombotic agent contg. urokinase - produced by maintaining pH neutral or weakly alkaline during each processing step for urokinase prodn.

Also Published As

Publication number Publication date
IN139029B (en) 1976-04-24
DE2502095B2 (en) 1978-06-29
CH611314A5 (en) 1979-05-31
AT341079B (en) 1978-01-25
FR2258396A1 (en) 1975-08-18
ES433961A1 (en) 1976-11-16
SE434956B (en) 1984-08-27
DE2502095A1 (en) 1975-07-24
AU7688374A (en) 1976-06-24
ATA43475A (en) 1977-05-15
GB1476092A (en) 1977-06-10
AU474513B2 (en) 1976-07-22
DE2502095C3 (en) 1979-02-22
CA1028262A (en) 1978-03-21
FR2258396B1 (en) 1977-11-18

Similar Documents

Publication Publication Date Title
DK235584D0 (en) PROCEDURE FOR MANUFACTURING A WHEEL PRODUCT
JPS5564799A (en) Multi-stage concentration and purification of interferon originated from human fibroblast
JPS57149228A (en) Novel erythropoietin and its preparation
ES397611A1 (en) Zirconium rinse for phosphate coated metal surfaces
DE3166201D1 (en) Process for the preparation of blood coagulation factors, and preparation containing factors ii and vii
GB1068817A (en) Isolation of urokinase
ES8100763A1 (en) Prothrombin complex concentrates,preparation and application thereof
GB1523546A (en) Process for producing a peptide in the presence or an enzyme
JPS5944286B2 (en) Purification method of bovine thrombin
GB1401737A (en) Anti-coagulant isolation
ES8605812A1 (en) Process for obtaining a factor XIII preparation and its use.
ATE111165T1 (en) HIGH-PERFORMANCE BIPOLAR MEMBRANES.
GB2099008B (en) Enzymatic process for the treatment of xanthan gums to improve the filtrability of their aqueous solutions
SE7500629L (en)
US4048014A (en) Method for obtaining urokinase
GB1507215A (en) Processes for producing immunoregulatory preparations
IE44077L (en) Technetium-99m-labelled diagnostic agent for kidney scanning
JPS5765183A (en) Sterilization and washing of immobilized lactase
EP0187670A3 (en) Process for recovering adsorbent for use in extracorporeal circulation treatment
JPS57150382A (en) Purification of super oxide dismutase
PL85201B1 (en)
JPS5659795A (en) Purification of nicotinic acid amide adenine dinucleotide
JPS5599191A (en) Purification of kallikrein in human urine
US3884760A (en) Production of urokinase
EP0446850A3 (en) Process for purifying recombinant human beta-interferon

Legal Events

Date Code Title Description
NUG Patent has lapsed

Ref document number: 7500629-6

Effective date: 19870914

Format of ref document f/p: F